Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 276
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT03460990 | A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F) | ||
| NCT02070744 | Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion | ||
| NCT01768663 | A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects | ||
| NCT03912233 | A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis | ||
| NCT06154447 | Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis | ||
| NCT02951182 | A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis | ||
| NCT03277196 | A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation | ||
| NCT00916474 | Virology Follow up Study in Subjects Previously Treated With Telaprevir | ||
| NCT01161537 | Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation | ||
| NCT00336479 | Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C | ||
| NCT06336096 | A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine | ||
| NCT02445053 | Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study) | ||
| NCT03655678 | A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia | ||
| NCT04474197 | Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype | ||
| NCT02875366 | A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation | ||
| NCT03150719 | A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF) | ||
| NCT00535847 | A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy | ||
| NCT04208529 | A Long-term Follow-up Study in Participants Who Received CTX001 | ||
| NCT03859531 | Gastrointestinal Study at Orkambi Therapy in CF Patients | ||
| NCT00780910 | Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy | ||
| NCT06886269 | A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose | ||
| NCT02544451 | Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor | ||
| NCT05455502 | A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548 | ||
| NCT05111145 | A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF) | ||
| NCT05660538 | Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN) | ||
| NCT04353817 | A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes | ||
| NCT01060566 | Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770 | ||
| NCT02015507 | An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With Ivacaftor | ||
| NCT03525548 | A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F) | ||
| NCT01467505 | An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients | ||
| NCT02516410 | A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation | ||
| NCT00973388 | VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers | ||
| NCT07074327 | Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants | ||
| NCT01685801 | Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function | ||
| NCT05955872 | A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147 | ||
| NCT04786262 | A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes | ||
| NCT00966602 | Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects | ||
| NCT01614457 | Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT) | ||
| NCT04599465 | A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF) | ||
| NCT06615570 | A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants | ||
| NCT01080222 | A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection | ||
| NCT06747572 | Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease | ||
| NCT05851157 | A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548 | ||
| NCT01705145 | Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation | ||
| NCT01790100 | A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C | ||
| NCT03304028 | MUCOviscidose EXacerbation Outils Connectés Education Thérapeutique | ||
| NCT06420765 | A Microneurography Study of NaV1.8 Inhibition in Healthy Adults | ||
| NCT01554085 | First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 | ||
| NCT03768089 | Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis | ||
| NCT03278314 | Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis |
